Hims & Hers Health (HIMS) said Tuesday it is expanding its weight loss products on its telehealth platform to include generic liraglutide and branded tirzepatide.
Tirzepatide is marketed by Eli Lilly (LLY) under the brand name Zepbound for obesity and Mounjaro for type 2 diabetes.
Neither Hims & Hers nor Eli Lilly immediately replied to a request for comment from MT Newswires.
Shares of Hims & Hers were up more than 7% in recent trading.
Price: 31.67, Change: +2.12, Percent Change: +7.17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.